Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17125686 | 0.94 | CNR1 (0.69) | CNR1LMNAPKMHPGDCASP2 | |
| SCHEMBL5866922 | 0.92 | CNR1 (0.68) | CNR1LMNAPKMCASP2FAAH | |
| SCHEMBL1456865 | 0.92 | CNR1 (0.68) | CNR1LMNAPKMCASP2FAAH | |
| SCHEMBL1456478 | 0.92 | CNR1 (0.68) | CNR1LMNAPKMCASP2FAAH | |
| SCHEMBL1695972 | 0.92 | CNR1 (0.68) | CNR1LMNAPKMCASP2FAAH | |
| SCHEMBL20206555 | 0.90 | CNR1 (0.56) | CNR1LMNAPKMHPGDCASP2 | |
| SCHEMBL19249120 | 0.89 | CASP2 (0.58) | CNR1LMNAPKMCASP2FAAH | |
| SCHEMBL21727959 | 0.88 | CNR1 (0.55) | CNR1LMNAPKMHPGDCASP2 | |
| SCHEMBL13328249 | 0.88 | LMNA (0.60) | CNR1LMNAPKMHPGDFAAH | |
| SCHEMBL8847608 | 0.88 | CNR1 (0.57) | CNR1LMNAPKMHPGDCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023018743-A1 | PH-RESPONSIVE NANOPARTICLE FOR DELIVERY OF RIBONUCLEOPROTEINS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-02-16 | — | — | WO | disclosed |
| US-10450307-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2019-05-09 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-07-26 | — | — | US | disclosed |
| EP-1615925-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | IPSEN PHARMA (FR) | 2009-05-27 | — | — | EP | disclosed |
| US-7495009-B2 | Imidazopyridine derivatives as melancortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-7495009-B2 | Imidazopyridine derivatives as melancortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450307-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CNR1 487/4885LMNA 1648/4885PKM 2868/4885 |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | CNR1 785/4885LMNA 3766/4885PKM 3869/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | CNR1 4712/4885LMNA 552/4885PKM 779/4885 |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CNR1 520/4885LMNA 2029/4885PKM 2946/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | CNR1 4712/4885LMNA 552/4885PKM 779/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | CNR1 4514/4885LMNA 984/4885PKM 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.